Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
253.00    -7.00 (-2.69%)
Bid:
253.00
Ask:
262.00
Spread: 9.00 (3.557%)
Market Cap: £226.58m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

4 Nov 2020 07:00

RNS Number : 1523E
Wilmington PLC
04 November 2020
Β 

4 November 2020

Wilmington plc

('Wilmington' or 'the Group')

Trading Update

Β 

Wilmington plc, the provider of data, information, education and networking services in Risk & Compliance, Healthcare and Professional knowledge areas today announces an update on trading for the three months to 30 September 2020. This statement is being made ahead of its Annual General Meeting ('AGM') which is taking place later today. The AGM is taking place as a closed meeting due to the restrictions imposed in response to Covid-19.

Β 

Trading Update

Β 

The Board is pleased to announce that financial results for the quarter have been encouraging and were ahead of management's previous expectations. Adjusted PBT was ahead of the corresponding period in the last financial year despite revenue being down around 6% on an underlying basis at constant currency due to the inability of the Group to run face-to-face training and events in the period.

Β 

The Group's Preliminary Results announced on 17 September 2020 demonstrated the extent to which the digital transformation of face-to-face events and training to virtual formats had been successful. The speed with which this transformation was delivered helped to mitigate a significant element of the potential first quarter revenue impact from Covid-19. Decisive action to reduce costs has also continued - the savings in direct costs as a result of this transition were augmented by an overhead reduction exercise that was undertaken over the summer resulting in the improved year-on-year profitability.

Β 

Each of the Group's three divisions has seen trading ahead of internal expectations. Notable performances were seen in our core subscription-led data businesses, which make up around 50% of Group revenues and which have continued to hold up well during the pandemic. Additionally, in Compliance, ICA Singapore has seen good registrations for new qualifications and in Professional, the investment banking training business was able to convert its summer intake programme to virtual formats and hence deliver revenue in line with the prior year.

Β 

Cashflow in the quarter was also better than previously expected with net debt as at 30 September 2020 of Β£28.0m (30 September 2019: Β£41.2m). In October, to secure its headroom, the Group extended by twelve months the term on its existing Β£65.0m revolving credit facility by exercising the pre-existing option that it had to do so. The facility will now expire on 3 July 2024.

Β 

Outlook

Β 

Following the strong first quarter trading performance the Group is on track to at least achieve the expectations for the half year that it set out in the Preliminary Results announcement on 17 September 2020. This is for revenue and profit in the first half to be in line with that achieved in the second half of the year to 30 June 2020.

Β 

Predictions for second half performance remain difficult at this current time due to the uncertainty over the extent to which the Group will be able to run face-to-face events in that period. Recent lockdowns and developments globally in the spread of Covid-19 are likely to delay the resumption of face-to-face activities and it is not possible to say at this stage when that resumption will be. The Group is currently in active discussions with customers over its key H2 events such as RISE National and is considering all alternatives around format and timing.

Β 

In the Preliminary Results announcement we set out a range of potential outcomes for H2 depending on whether or not we could run face-to-face events and training. Recent trading experience leads us to believe that a fully virtual H2 would deliver better revenue and profitability than we guided to at that time as the lower end of the potential range. So whilst the chances of that scenario occurring have increased in recent weeks as the pandemic has developed, we feel increasingly confident in our ability to mitigate some of the associated financial effects of that potential outcome.

Β 

The Group plans to announce its Interim Results for the six months ended 31 December 2020 on Thursday 18 February 2021.

Β 

Β 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

Β 

Β 

ForΒ furtherΒ information,Β pleaseΒ contact:

Β 

WilmingtonΒ plc 020Β 7490 0049

Β 

Mark Milner, Chief Executive Officer

Richard Amos, Chief Financial Officer

Β 

FTI Consulting 020 3727 1000

Charles PalmerΒ / Dwight Burden / Emma Hall / Debbie Oluwaseyi Sonaike

Β 

Β 

NotesΒ toΒ EditorsΒ 

Wilmington is the recognised knowledge leader and partner of choice for data, information, education and networking in Risk & Compliance, Healthcare and Professional areas. Wilmington employs close to 1,000 people and sells to around 120 countries. Wilmington plc is listed on the main market of the London Stock Exchange.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTUOVNRRNUARAA
Date   Source Headline
19th Mar 20184:18 pmRNSBoard Change - Correction
19th Mar 201811:34 amRNSHolding(s) in Company
16th Mar 20181:06 pmRNSBoard Change
15th Mar 20183:36 pmRNSHolding(s) in Company
2nd Mar 20182:13 pmRNSDirector/PDMR Shareholding
1st Mar 20189:00 amRNSVoting Rights and Capital
26th Feb 20188:34 amRNSDirector/PDMR Shareholding
22nd Feb 20183:49 pmRNSHolding(s) in Company
22nd Feb 20187:00 amRNSInterim Results
22nd Feb 20187:00 amRNSAppointment of Martin Morgan as Chairman
14th Feb 20182:50 pmRNSHolding(s) in Company
1st Feb 20189:10 amRNSHolding(s) in Company
1st Feb 20189:00 amRNSVoting Rights and Capital
4th Jan 20187:00 amRNSAcquisition of Interactive Medica
2nd Jan 20189:00 amRNSVoting Rights and Capital
18th Dec 20174:43 pmRNSNotification of Interim Results
1st Dec 20177:00 amRNSVoting Rights and Capital
29th Nov 20177:00 amRNSAppointment of new Chief Financial Officer
23rd Nov 201710:34 amRNSDirector/PDMR Shareholding
2nd Nov 20172:43 pmRNSResult of AGM
2nd Nov 20177:00 amRNSAGM and Q1 Trading Update
1st Nov 20179:12 amRNSVoting Rights and Capital
6th Oct 20175:58 pmRNSHolding(s) in Company
5th Oct 20173:45 pmRNSHolding(s) in Company
5th Oct 20173:44 pmRNSHolding(s) in Company
2nd Oct 20172:49 pmRNSVoting Rights and Capital
29th Sep 20179:27 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSProposed Board Change
21st Sep 20171:47 pmRNSDirector/PDMR Shareholding
20th Sep 201711:50 amRNSShare Awards
18th Sep 20172:01 pmRNSVoting Rights and Capital
14th Sep 20172:48 pmRNSDirector/PDMR Shareholding
14th Sep 20179:33 amRNSDirector/PDMR Shareholding
13th Sep 20174:03 pmRNSDirector/PDMR Shareholding
13th Sep 20177:01 amRNSBoard Change
13th Sep 20177:00 amRNSFinal Results
22nd Aug 20171:52 pmRNSNotification of Final Results
18th Aug 20171:11 pmRNSHolding(s) in Company
1st Aug 201712:21 pmRNSVoting Rights and Capital
3rd Jul 20177:00 amRNSVoting Rights and Capital
28th Jun 20179:44 amRNSDirector/PDMR Shareholding
21st Jun 20173:05 pmRNSHolding(s) in Company
16th Jun 20174:35 pmRNSPrice Monitoring Extension
1st Jun 201712:00 pmRNSVoting Rights and Capital
19th May 201711:56 amRNSHolding(s) in Company
18th May 20177:00 amRNSTrading Statement
4th May 20177:00 amRNSProperty Disposal
3rd May 20171:56 pmRNSHolding(s) in Company
2nd May 20172:21 pmRNSVoting Rights and Capital
3rd Apr 201711:33 amRNSVoting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.